Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein-Barr virus infection.

Orphanet Journal of Rare Diseases
Honghao MaRui Zhang

Abstract

We intended to investigate the clinical features of paediatric patients with chronic active Epstein-Barr virus infection (CAEBV) and to examine the effectiveness of the L-DEP regimen before haematopoietic stem cell transplantation (HSCT). A retrospective analysis was performed on 35 patients with CAEBV at Beijing Children's Hospital from January 2016 to January 2020. The efficacy and adverse events of the L-DEP regimen were evaluated. The median age of the 35 patients was 7.0 years old (range 2.5-17.5 years). Twenty-eight patients achieved a clinical response (80.0%, 22 in clinical CR, 6 in clinical PR) after L-DEP. In terms of virological response, 7 patients (20%) were assessed as having virological CR, and 23 patients (65.7%) had virological PR. Finally, 29 patients underwent allo-HSCT. The median survival time was 18 months (2-50 months). The 3-year overall survival rates in patients treated with chemotherapy only (n = 6) and chemotherapy followed by HSCT (n = 25) were 33.3% and 75.4%, respectively. After L-DEP 1st treatment and L-DEP 2nd treatment, the EBV-DNA loads in blood and plasma were significantly reduced compared with those before chemotherapy (median: 4.29 × 105 copies/ml vs. 1.84 × 106 copies/ml, Mann-Whitney U: ...Continue Reading

References

Dec 26, 1996·The New England Journal of Medicine·M J NewportM Levin
Feb 25, 2003·The Journal of Infectious Diseases·Hiroshi KimuraUNKNOWN Japanese Association for Research on Epstein-Barr Virus and Related Diseases
Sep 15, 2005·British Journal of Haematology·Miki AndoKazuo Oshimi
Aug 29, 2006·Pediatric Blood & Cancer·Jan-Inge HenterGritta Janka
May 15, 2013·Korean Journal of Pathology·Mineui HongHeejung Park
May 8, 2014·Microbes and Infection·Masanao MurakamiMasanori Daibata
Feb 18, 2017·International Journal of Hematology·Akihisa SawadaKeisei Kawa
Jan 30, 2018·Frontiers in Immunology·Hiroshi Kimura, Jeffrey I Cohen
Mar 15, 2018·Frontiers in Immunology·David Michalovich, Sergey Nejentsev
May 26, 2018·The Journal of Allergy and Clinical Immunology·Emily S J EdwardsStuart G Tangye
Sep 21, 2019·The Journal of Experimental Medicine·Rémy RodriguezSylvain Latour
Dec 18, 2019·Reviews in Medical Virology·Takayuki MurataHiroshi Kimura
Mar 13, 2020·The Journal of Clinical Investigation·Gaspard KernerJacinta Bustamante

❮ Previous
Next ❯

Software Mentioned

SIFT
GraphPad Prism
Polyphen2
SPSS

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.